论文部分内容阅读
115例重型病毒性肝炎(简称重型肝炎)分三组治疗观察,其中肝细胞生长因子(HGF)组30例存活22例(73.33%);人胎肝细胞(FLC)组45例存活28例(62.22%);基础治疗组(基治组)40例存活10例(40.00%)。经统计分析HGF 和FLC 组明显优于基治组,而HGF 组和FLC 组间无明显差异,提示HGF 可以替代FCL 作为治疗重型肝炎的有效药物。
115 cases of severe hepatitis were divided into three groups. Among them, 30 cases of HGF group survived in 22 cases (73.33%) and 45 cases of FH group (28 cases) survived 62.22%). In the basic treatment group, 40 patients survived in 10 cases (40.00%). Statistical analysis HGF and FLC group was significantly better than the base group, and HGF group and FLC group no significant difference, suggesting that HGF can replace FCL as an effective drug for the treatment of severe hepatitis.